Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
What the film says
DNX-2401, a rebuilt cold virus that multiplies only in tumor cells, has been injected into glioblastomas for over a decade; a few patients lived for years. The limit is delivery: a needle reaches one spot; glioblastoma is everywhere.
The idea: hire cells that seek out tumors, and let them carry the virus in.
Mesenchymal stem cells from donor bone marrow home naturally to inflamed tissue, which describes a tumor exactly. They are loaded with the virus. Then, through a catheter threaded from the groin to the brain's arteries, they ride the tumor's own blood supply and unload the virus where they land.
This trial, at MD Anderson with Frederick Lang, is the first in people, finding a safe dose. Public record; not medical advice.
Sources behind this film
Lang FF. J Clin Oncol, 2018
DNX-2401 (Delta-24-RGD) is a tumor-selective adenovirus injected into glioblastomas for over a decade; a few long survivors
DNX-2401 (Delta-24-RGD) is a tumor-selective adenovirus injected into glioblastomas for over a decade; a few long survivors; A needle reaches one spot; glioblastoma is diffuse; Donor bone-marrow mesenchymal stem cells home to tumors; loaded with the virus; Catheter from the groin to the brain's arteries; infused into the tumor's blood supply (+1 more lines)
Yong RL. Cancer Res, 2009
Donor bone-marrow mesenchymal stem cells home to tumors; loaded with the virus
Chen SR. J Neurointerv Surg, 2022
Catheter from the groin to the brain's arteries; infused into the tumor's blood supply
The drug
PRIMARY OBJECTIVES: I. To determine the maximal tolerated dose (MTD) of allogeneic bone marrow-derived human mesenchymal stem cells (BM-hMSCs) loaded with the oncolytic adenovirus DNX-2401 (BM-hMSCs-DNX2401) administered by intra-arterial injection (i.e., transfemoral endovascular intracranial injection) in patients with recurrent glioblastoma (GBM), IDH-mutant astrocytoma grade 4, gliosarcoma, or wild-type IDH-1 anaplastic astrocytoma. II.
To determine the local and systemic toxicity of allogeneic BM-hMSCs-DNX2401 administered by intra-arterial injection (i.e., transfemoral endovascular intracranial injection) in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma. III.
The study
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.